The Potential Role of Advanced Technologies for Virus Detection in Development and Regulation of Vaccines

References

1. 1.↵
   1. Sweet B. H.,
   2. Hilleman M. R.

   The vacuolating virus, S.V. 40. Proc. Soc. Exp. Biol. Med. 1960, 105 (2), 420–427.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Sierra-Honigmann A.,
   2. Krause P. R.

   Live oral poliovirus vaccines do not contain detectable simian virus 40 (SV40) DNA. Biologicals 2000, 28 (1), 1–4.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Strickler H. D.,
   2. Rosenberg P. S.,
   3. Devesa S. S.,
   4. Hertel J.,
   5. Fraumeni J. F. Jr..,
   6. Goedert J. J.

   Contamination of poliovirus vaccines with simian virus 40 (1955–1963) and subsequent cancer rates. J. Am. Med. Assoc. 1998, 279 (4), 292–295.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Strickler H. D.

   A multicenter evaluation of assays for detection of SV40 DNA and results in masked mesothelioma specimens. Cancer Epidemiol. Biomarkers Prev. 2001, 10 (5), 523–532.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Khan A. S.,
   2. Maudru T.,
   3. Thompson A.,
   4. Muller J.,
   5. Sears J. F.,
   6. Peden K. W.

   The reverse transcriptase activity in cell-free medium of chicken embryo fibroblast cultures is not associated with a replication-competent retrovirus. J. Clin. Virol. 1998, 11 (1), 7–18.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Robertson J. S.,
   2. Nicolson C.,
   3. Riley A. M.,
   4. Bentley M.,
   5. Dunn G.,
   6. Corcoran T.,
   7. Schild G. C.,
   8. Minor P.

   Assessing the significance of reverse transcriptase activity in chick cell–derived vaccines. Biologicals 1997, 25 (4), 403–414.

   OpenUrlCrossRefPubMed
7. 7.↵
   World Health Organization. Reverse transcriptase activity in chicken cell–derived vaccine. Wkly Epidemiol. Rec. 1998, 73, 209–312.

   OpenUrlPubMed
8. 8.↵
   1. Tsang S. X.,
   2. Switzer W. M.,
   3. Shanmugam V.,
   4. Johnson J. A.,
   5. Goldsmith C.,
   6. Wright A.,
   7. Fadly A.,
   8. Thea D.,
   9. Jaffe H.,
   10. Folks T. M.,
   11. Heneine W.

   Evidence of avian leukosis virus subgroup E and endogenous avian virus in measles and mumps vaccines derived from chicken cells: investigation of transmission to vaccine recipients. J. Virol. 1999, 73 (7), 5843–5851.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Shahabuddin M.,
   2. Sears J. F.,
   3. Khan A. S.

   No evidence of infectious retroviruses in measles virus vaccines produced in chicken embryo cell cultures. J. Clin. Microbiol. 2001, 39 (2), 675–684.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Victoria J. G.,
    2. Wang C.,
    3. Jones M. S.,
    4. Jaing C.,
    5. McLoughlin K.,
    6. Gardner S.,
    7. Delwart E. L.

    Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J. Virol. 2010, 84 (12), 6033–6040.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. McClenahan S. D.,
    2. Krause P. R.,
    3. Uhlenhaut C.

    Molecular and infectivity studies of porcine circovirus in vaccines. Vaccine 2011, 29 (29), 4745–4753.

    OpenUrlPubMed
12. 12.↵
    1. Dubin G.,
    2. Toussaint J. F.,
    3. Cassart J. P.,
    4. Howe B.,
    5. Boyce D.,
    6. Friedland L.,
    7. Abu-Elyazeed R.,
    8. Poncelet S.,
    9. Han H. H.,
    10. Debrus S.

    Investigation of a regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human rotavirus vaccine, Rotarix: approach and outcome. Hum. Vaccin. Immunother. 2013, 9 (11), 2398–2408.

    OpenUrlPubMed
13. 13.↵
    1. McClenahan S.,
    2. Uhlenhaut C.,
    3. Krause P. R.

    Regulatory approaches for control of viral contamination of vaccines. PDA J. Pharm. Sci. Technol. 2011, 65 (6), 557–562.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. McClenahan S.,
    2. Uhlenhaut C.,
    3. Krause P.

    Optimization of virus detection in cells using massively parallel sequencing. Biologicals 2014, 42 (1), 34–41.

    OpenUrlPubMed
15. 15.↵
    1. McClenahan S. D.,
    2. Uhlenhaut C.,
    3. Krause P. R.

    Evaluation of cells and biological reagents for adventitious agents using degenerate primer PCR and massively parallel sequencing. Vaccine 2014, in press.
16. 16.↵
    1. Onions D.,
    2. Kolman J.

    Massively parallel sequencing, a new method for detecting adventitious agents. Biologicals 2010, 38 (3), 377–380.

    OpenUrlPubMed
17. 17.↵
    1. Onions D.,
    2. Côté C.,
    3. Love B.,
    4. Toms B.,
    5. Koduri S.,
    6. Armstrong A.,
    7. Chang A.,
    8. Kolman J.

    Ensuring the safety of vaccine cell substrates by massively parallel sequencing of the transcriptome. Vaccine 2011, 29 (41), 7117–7121.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Ma H.,
    2. Galvin T. A.,
    3. Glasner D. R.,
    4. Shaheduzzaman S.,
    5. Khan A. S.

    Identification of a novel rhabdovirus in Spodoptera frugiperda cell lines. J. Virol. 2014, 88 (12), 6576–6585.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Estep R. D.,
    2. Messaoudi I.,
    3. Wong S. W.

    Simian herpesviruses and their risk to humans. Vaccine. 2010, 28 (Suppl 2), B78–B84.

    OpenUrlCrossRefPubMed
20. 20.↵
    United States Food and Drug Administration. Update on Recommendations for the Use of Rotavirus Vaccines. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm212140.htm.
21. 21.↵
    Vaccines and Related Biological Products Advisory Committee. Finding of PCV DNA Sequences in Rotavirus Vaccines. May 7, 2010.